Navigation Links
Emerging SARS-Like Virus Well-Suited to Attack Humans: Study
Date:2/19/2013

TUESDAY, Feb. 19 (HealthDay News) -- The new SARS-like "coronavirus" that first emerged in the Middle East can invade the lungs and immune system as easily as the common cold, according to a new study.

But in the event of a large-scale outbreak, researchers in Switzerland found the virus -- known as HCoV-EMC -- may be treatable with components of the immune system, known as interferons. This immunotherapy has shown promise in the treatment of the respiratory disease SARS and hepatitis C, the study authors said.

"Surprisingly, this coronavirus grows very efficiently on human epithelial cells," said study co-author Volker Thiel of the Institute of Immunobiology at Kantonal Hospital in St. Gallen, in a news release from the American Society for Microbiology. Epithelial cells line hollow organs and glands.

"The other thing we found is that the viruses [HCoV-EMC, SARS, and the common cold virus] are all similar in terms of host responses: they don't provoke a huge innate immune response," he said.

The study was published online Feb. 19 in mBio.

HCoV-EMC, which may have jumped from animal to human very recently, was first isolated in June after a man in Saudi Arabia died from a severe respiratory infection and kidney failure. Following his death, health officials identified 11 more people infected with the virus, the latest in Great Britain. So far, six of the 12 people with known infections have died. Nearly all patients have lived or traveled in the Middle East.

Concerns have been raised that the new strain could trigger a pandemic similar to the SARS outbreak of 2002-03, which infected more than 8,000 people and killed 774.

"We don't know whether the cases we observed are the tip of the iceberg, or whether many more people are infected without showing severe symptoms," noted Thiel.

The World Health Organization on Saturday said that doctors should test patients for the new coronavirus if they have unexplained pneumonia or unexplained complicated respiratory illness not responding to treatment.

So far, no cases of the coronavirus have been reported in the United States, according to the U.S. Centers for Disease Control and Prevention.

To test the new virus, the researchers used cultured bronchial cells to mimic the lining of the human airway. Although this lining is a key barrier against respiratory viruses, the study revealed these cells didn't mount a big defense against HCoV-EMC. Instead, they found human lungs are highly susceptible to the virus, which can multiply at a faster initial rate than SARS.

The study authors noted, however, that pre-treating the airway with proteins that play a critical role in immune response to infections -- known as lambda-type interferons -- significantly reduced the number of infected cells.

Although their findings suggest there is promise for an effective treatment against HCoV-EMC, the researchers added ongoing cooperation between scientists and health agencies around the world is needed to prevent outbreaks of this virus and other diseases.

More information

The World Health Organization provides more information on coronavirus infections.

-- Mary Elizabeth Dallas

SOURCE: American Society for Microbiology, news release, Feb. 19, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. OLEV selected as 1 of 10 emerging technologies in 2013 by World Economic Forum
2. Emerging cancer drugs may drive bone tumors
3. NIH scientists reflect on gains in emerging infectious disease awareness, research and response
4. Chicago Hat Designer Tonya Gross Selected by Online Retailer Zappos.com for 2013 Emerging Designer Program
5. Queens scientist is named Emerging Scientist 2012
6. CWRUs Maxwell J. Mehlmans book examines issues emerging in genetic engineering
7. Expanding database enables discoveries in emerging field of metabolomics
8. New Immune-Deficiency Illness Emerging in East Asia
9. CDC Warns of Another Emerging Tick-Borne Threat
10. New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
11. Study Finds New SARS-Like Virus Spread Through Bats, Pigs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Emerging SARS-Like Virus Well-Suited to Attack Humans: Study
(Date:6/28/2017)... ... June 28, 2017 , ... The Wharton School’s Aresty Institute ... as a kick-off to the fifth annual CEO Connection Mid-Market Convention. , ... of Pennsylvania campus, followed by the two-day convention, which will target C-suite executives ...
(Date:6/28/2017)... Santa Clara, CA (PRWEB) , ... June 28, 2017 , ... ... is hosting a free AFM Luncheon for all SEMICONWest attendees and Park ... The luncheon will feature talks from Dr. Sang-il Park, Chairman & CEO of Park ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... and financial planning assistance to clients in southern Montana, is announcing a focused ... Zoo Montana. , The outreach programs offered by Zoo Montana provide students with ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers Insurance Agency, a ... northern Virginia and DC, is announcing a cooperative charity event in conjunction with ... other disorders that lead to memory impairment. , The Insight Memory Care Center ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... announced the appointment of Mike Finnegan to the position of Executive Vice President, ... of experience in healthcare technology, telehealth and medical device sales leadership. He has ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that the U.S. Food and Drug Administration ... June 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning ... manufacturing facility is a measure of the progress we ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
Breaking Medicine Technology: